Next Day Disclosure Return
Filed with HKEX · · 6 pages · English
IMPACT Therapeutics, Inc. on 6ix
Later from IMPACT Therapeutics
- Articles of association
- IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand
- 2026 Interim Report
- Voluntary announcement - positive CHMP opinion for senaparib, as potential first-line maintenance treatment of advanced epithelial ovarian, fallopian tube, and primary peritoneal cancer
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Follow IMPACT Therapeutics into a list and get an email when it puts out news.
Follow IMPACT Therapeutics